Thymosin Alpha 1 Plus Routine Treatment for the Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis

Ailing Cao, Fanchao Feng and Xianmei Zhou

Department of Respiratory Medicine, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China

ABSTRACT

This systematic review was conducted to assess the curative effect of Thymosin alpha 1 in the acute exacerbation of chronic obstructive pulmonary disease (AECOPD) patients. Six electronic databases including EMBASE, PubMed, Cochrane Library, China National Knowledge Infrastructure Database, Chinese Biomedical Database, and Wanfang Database were searched for eligible papers focusing on the thymosin alpha 1 treatment in AECOPD patients. The effectiveness outcomes included T cell subset, pulmonary function, arterial blood gases, and the length of hospital stay. Stata and Review Manager Software were used for data analysis. Thirty-nine randomised controlled trials with a total of 3,329 patients were included. Compared with the control treatment, Thymosin alpha 1 therapy significantly improved forced expiratory volume in 1 second [MD = 0.29, 95% (0.26, 0.32), p <0.001] and the ratio of forced expiratory volume in the first second to forced vital capacity [MD = 6.24, 95% (3.83, 8.65), p <0.001], increased the arterial partial pressure of oxygen [MD = 7.24, 95% (3.42, 11.07), p = 0.0002], lowered the arterial partial pressure of carbon dioxide [MD = -5.85, 95% (-9.38, -2.33), p = 0.001], shortened the length of hospital stay [MD = -5.39, 95% (-7.82, -2.97), p <0.001], raised the level of CD4$^+$ T lymphocytes count [MD = 7.54, 95%(6.66, 8.41), p <0.001] and the ratio of CD4$^+$/CD8$^+$ [MD = 0.40, 95% (0.34, 0.46), p <0.001], and decreased level of CD8$^+$ T lymphocytes count [MD = -2.74, 95% (-3.86, -1.63), p <0.001]. Thymosin alpha 1 could significantly boost the immune function, and improve pulmonary function and arterial blood gas of AECOPD patients than routine treatment only. More high-quality randomised controlled trials are needed to further confirm Thymosin alpha 1 efficacy.

Key Words: Thymosin alpha 1, Efficacy, Acute exacerbation of chronic obstructive pulmonary disease, Meta-analysis.

How to cite this article: Cao A, Feng F, Zhou X. Thymosin Alpha 1 Plus Routine Treatment for the Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. *J Coll Physicians Surg Pak* 2024; **34(12)**:1497-1507.

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is now one of the top three causes of death worldwide. Worldwide COPD affects 9-10% of the adult population and in Asian countries, such as China, the prevalence in people aged over 40 years is 13.7%.[1] COPD represents an important public health challenge that is both preventable and treatable. A principal factor affecting COPD-related mortality is the acute exacerbation of COPD (AECOPD). Exacerbation contributes to the overall severity, including quality of life, rates of hospitalisation and readmission, and disease progression.

Correspondence to: Dr. Xianmei Zhou, Department of Respiratory Medicine, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Qinhuai District, Nanjing 210000, Jiangsu, China
E-mail: zhouxianmeijsszyy@163.com

At the moment, the conventional treatment protocol for AECOPD includes anti-infection, anti-inflammatory, bronchial expansion, mechanical ventilation, and respiratory therapy. The application of glucocorticoids is beneficial to patients. However, the effects of these measures are limited. High-dose glucocorticoids provide little benefit in terms of improving lung function and may have long-term detrimental effects.[2] Approximately, one-third of patients with COPD experience one or more exacerbations every year.[3] Hence, the clinical efficacy of AECOPD needs to be further improved.

In COPD there is a characteristic pattern of inflammation with increased numbers of neutrophils, macrophages, T-lymphocytes, and B-lymphocytes in the airway lumen. T-lymphocytes comprise a subpopulation of T CD4$^+$ lymphocytes that regulate immune response through secretion of cytokines. A disruption in the regulatory mechanisms of the T-lymphocytes could result in the development and perpetuation of inflammation in COPD.[4]

Thymosin alpha 1 is a 28 amino acid peptide originally isolated from the thymus that has been recognised for modifying, enhancing, and restoring the immune function. It is a peptide hormone that is endogenously produced by the thymus gland and potentiates T cell-mediated immune responses *via* differen-

tiation and maturation of T-cell progenitor cells, activation of dendritic and natural killer cells, and stimulation of cytokine-mediated inflammation.[5] The synthetic form of thymosin alpha 1, thymalfasin, is approved in more than 35 countries for the treatment of immunocompromised states and malignancies, as an enhancer of vaccine response, and as a means of curbing morbidity and mortality in sepsis and numerous infections. Clinical trials had confirmed that Thymosin alpha 1, could enhance the immune function of AECOPD patients, suppress the inflammatory reaction, and ameliorate the patients' quality of life and pulmonary function.[6,7] Nevertheless, no relevant evidence-based evaluations have been published until now. Therefore, a systematic review and meta-analysis was conducted to integrate information presented in studies on the effectiveness of Thymosin α1 in the treatment of AECOPD patients.

METHODOLOGY

This systematic review was conducted following the reporting items for systematic reviews and meta-analyses guidelines. Published researches were retrieved from six databases, including EMBASE, PubMed, Cochrane Library, China National Knowledge Infrastructure Database, Wanfang Database, and Chinese Biomedical Database (from established to August 2023). The first two authors independently searched studies in electronic databases. The search strategy was as follows:

1 "Pulmonary Disease, Chronic Obstructive"[Mesh Terms]

2 "Lung Diseases, Obstructive"[MeSH Terms]

3 COPD [Title/Abstract] OR COAD [Title/Abstract] OR chronic obstructive airway disease [Title/Abstract] OR chronic obstructive lung disease [Title/Abstract] OR chronic obstructive pulmonary disease [Title/Abstract] OR chronic obstructive airflow disease [Title/Abstract] OR chronic obstructive respiratory disease [Title/Abstract] OR emphysema [Title/Abstract] OR chronic bronchitis [Title/Abstract] OR chronic airflow obstruction [Title/Abstract]

4, 1 or 2 or 3

5 thymosin [Title/Abstract]) OR thymosin alpha 1 [Title/Abstract]) thymalfasin [Title/Abstract])

6, 4, and 5

The criteria for the studies to be included in the meta-analysis were as follows: All patients in study were diagnosed as AECOPD according to Global Initiative for Chronic Obstructive Lung Disease criteria; type of study was randomised controlled trial (RCT); the experimental group was given Thymosin alpha 1 plus routine complex treatment, whereas the intervention in the control group was routine complex treatment; at least one of the following outcomes was required in the present study: T cell subset, pulmonary function, arterial blood gases, and / or the length of hospital stay. Relevant studies were manually removed if any of the following criteria were identified: Duplicated articles; Incomplete literature information; studies whose baseline data were significantly inconsistent.

The primary indicator of the present study was the T cell subset, including percentages of $CD4^+$ T lymphocytes, $CD8^+$ T lymphocytes, and the ratio of $CD4^+/CD8^+$. The secondary indicators were arterial blood gases (arterial partial pressure of oxygen and arterial partial pressure of carbon dioxide), the length of hospital stay, and pulmonary function (forced expiratory volume in the first second and the ratio of forced expiratory volume in the first second to forced vital capacity).

The first two authors independently extracted data from the studies included. Data extracted from eligible studies included the first author's name, publication date, study characteristics, and participants' characteristics (age, sample size, details of interventions, and outcomes). If different results were generated, the third author assessed the differences in the forms and had discussion between the first and second authors to come to an agreement.

The methodological quality of the eligible studies was assessed independently by first two authors based on the criteria in the Cochrane evaluation handbook of RCTs 5.1.0,[8] which included five parameters: Sequence generation; allocation concealment; blinding of participants and study personnel and blinding of outcome assessments; incomplete outcome data; and selective outcome reporting. The studies were graded as having low, high, or unclear risk of bias. This course had to be cross-checked in order to ensure accuracy and reliability. The disagreements between the two investigators were resolved by consultation with the third author.

The RevMan 5.3 (Cochrane Collaboration) and Stata 14.0 software were used to calculate the statistical analysis. As continuous variables, pulmonary function, arterial blood gases, length of hospital stay, and T cell subset were assessed using mean difference (MD) and corresponding 95% CIs. I^2 statistics were used to assess the statistical heterogeneity among studies. The random model was conducted in the presence of heterogeneity ($I^2 \geq 50\%$). Otherwise, the fixed model was used ($I^2 < 50\%$). The statistical significance was assessed for $p < 0.05$. Funnel plot and Egger's regression asymmetry test were performed to detect potential publication bias. Evidence of asymmetry from Egger's test was considered to be significant at $p < 0.1$, A value of $p < 0.05$ was considered statistically significant. Sensitivity analysis was performed by sequential omission of individual studies and re-conducting meta-analysis of the remaining studies.

RESULTS

Based on the search criteria, the initial database search identified 443 potentially relevant possible studies. A total of 54 Records were identified after removing duplicates and screening the titles and abstracts. Fifteen trials were excluded for the following reasons: Retrospective study (n = 6), no relative outcomes (n = 8), and duplicate data (n = 1). Finally, 39 clinical trials were involved in this meta-analysis. The flowchart of the detailed searching steps for this meta-analysis is described in Figure 1.

Table I: Baseline characteristics of included studies.

Study, year	Age, years (Mean ± SD/range)	Sample size (N)	Interventions	Course of treatment	Outcome
Jia et al. 2015[9]	T:70.10 ± 5.65; C:69.86 ± 5.19	T:42 C:42	T: Tα1+the routine complex treatment; C: placebo+the routine complex treatment	4 weeks	①②③
Wu 2019[10]	79.6 ± 3.7; 80.2 ± 4.4	31/29	T: Tα1+the routine complex treatment; C: the routine complex treatment C: Antibiotics, conventional treatment	10 - 14d	②
Sun et al. 2019[11]	73.02 ± 4.22; 72.54 ± 3.65	48/48	T: Tα1+the routine complex treatment; C: the routine complex treatment	14d	②
Fan YJ 2017[12]	51.7 ± 2.19; 45.2 ± 3.16	46/46	T: Tα1+the routine complex treatment; C: the routine complex treatment	12 weeks	②
Xie 2016[13]	67. 71 ± 12. 39; 67. 64 ± 12. 33	30/30	T: Tα1+the routine complex treatment; C: the routine complex treatment	14d	①
Tong et al. 2013[14]	67.1 ± 7.2; 69.4 ± 4.5	43/40	T: Tα1+the routine complex treatment; C: the routine complex treatment	7d	①②③
Fan 2017[15]	70.35 ± 3.47; 69.40 ± 3.12	45/45	T: Tα1+the routine complex treatment; C: the routine complex treatment	14d	①②
Yang et al. 2018[16]	58.44 ± 7.26; 58.12 ± 7.25	40/40	T: Tα1+the routine complex treatment; C: the routine complex treatment	10d	①
Zhou 2018[17]	64.54 ± 4.58; 64.64 ± 4.60	39/39	T: Tα1+the routine complex treatment; C: the routine complex treatment	10d	①
Yu 2018[18]	57.9 ± 6.5; 58.4 ± 7.8	35/35	T: Tα1+the routine complex treatment; C: the routine complex treatment	10d	①②③
Ye 2019[19]	67.3 ± 4.8; 67.0 ± 4.5	53/52	T: Tα1+the routine complex treatment; C: the routine complex treatment	10d	①②
Hu 2018[20]	76.37 ± 8.04; 74.13 ± 7.51	30/30	T: Tα1+the routine complex treatment; C: the routine complex treatment	4 weeks	①
Wang et al. 2017[21]	59.67 ± 3.25; 58.62 ± 4.31	50/50	T: Tα1+the routine complex treatment; C: the routine complex treatment	14d	①
Shao 2019[22]	66.34 ± 6.13; 66.7 5± 6.74	33/32	T: Tα1+the routine complex treatment; C: the routine complex treatment	10d	②
Zhang 2016[23]	70.5 ± 2.7; 70.8 ± 2.5	45/45	T: Tα1+the routine complex treatment; C: the routine complex treatment	8-10d	②
Zhao et al. 2016[24]	53.4±6.1; 54.1±6.3	30/30	T: Tα1+the routine complex treatment; C: the routine complex treatment	10d	①②
Cai 2019[25]	62.8 ± 8.3; 62.7 ± 8.2	33/32	T: Tα1+the routine complex treatment; C: the routine complex treatment	7d	①
Jin 2018[26]	74.5 ± 2.8; 73.8 ± 2.6	43/43	T: Tα1+the routine complex treatment; C: the routine complex treatment	7d	①②
Guo 2016[27]	71.47 ± 4.12; 71.35 ± 4.26	25/25	T: Tα1+the routine complex treatment; C: the routine complex treatment	10d	②
Quan 2019[28]	73.30 ± 0.28; 73.24 ± 0.26	44/43	T: Tα1+the routine complex treatment; C: the routine complex treatment	10d	①②
Wang 2019[29]	71.98 ± 5.66; 71.54 ± 4.34	35/35	T: Tα1+the routine complex treatment; C: the routine complex treatment	8-10d	②
Zhang 2020[30]	70.4 ± 2.5; 70.5 ± 2.4	35/35	T: Tα1+the routine complex treatment; C: the routine complex treatment	7-14d	②
Zhao et al. 2018[31]	69.5 ± 2.6; 69.9 ± 2.7	65/65	T: Tα1+the routine complex treatment; C: the routine complex treatment	8-10d	②
Peng 2015[32]	70.5 ± 9.8; 69.0 ± 9.5	67/67	T: Tα1+the routine complex treatment; C: the routine complex treatment	10d	②
Cui et al. 2012[33]	65-85; 67-84	15/15	T: Tα1+the routine complex treatment; C: the routine complex treatment	7d	①
Jiao et al. 2017[34]	70.82 ± 2.20; 70.23 ± 2.23	41/41	T: Tα1+the routine complex treatment; C: the routine complex treatment	8d	①
Liu 2014[35]	68.7 ± 4.9; 67.9 ± 5.2	40/40	T: Tα1+the routine complex treatment; C: the routine complex treatment	10d	①②③
Li J 2018[36]	40-87; 43-85	42/42	T: Tα1+the routine complex treatment; C: the routine complex treatment	10d	②③
Lin et al. 2016[37]	65.27 ± 4.21; 62.86 ± 5.87	40/40	T: Tα1+the routine complex treatment; C: the routine complex treatment	14d	①②
Le 2013[38]	69.2 ± 2.3; 69.7 ± 2.6	40/40	T: Tα1+the routine complex treatment; C: the routine complex treatment	8-10d	②
Wu et al. 2017[39]	63.4 ± 4.2; 64.5 ± 4.8	38/37	T: Tα1+the routine complex treatment; C: the routine complex treatment	14d	①②③
Jiang 2018[40]	68.53 ± 8.29; 69.47 ± 8.19	133/124	T: Tα1+the routine complex treatment; C: the routine complex treatment	7d	①②
Yu et al. 2017[41]	65.5 ± 6.8; 65.3 ± 6.4	44/44	T: Tα1+the routine complex treatment; C: the routine complex treatment	14d	①②③
Ju 2016[42]	65.2 ± 2.4; 65.4 ± 2.6	46/42	T: Tα1+the routine complex treatment; C: the routine complex treatment	10d	①②
Su 2018[43]	53.4 ± 3.2; 53.4 ± 3.2	30/30	T: Tα1+the routine complex treatment; C: the routine complex treatment	14d	②
Li et al. 2007[44]	70.7 ± 11.7; 69.9 ± 12.3	56/52	T: Tα1+the routine complex treatment; C: the routine complex treatment	14d	①
Liu et al. 2014[45]	71.8 ± 9.76; 69.6 ± 8.81	60/60	T: Tα1+the routine complex treatment; C: the routine complex treatment	14d	①④
Shao 2013[46]	NR	40/40	T: Tα1+the routine complex treatment; C: the routine complex treatment	14d	①④
Jin et al. 2012[47]	71.2 ± 19.8; 74 ± 23.4	37/40	T: Tα1+the routine complex treatment; C: the routine complex treatment	10d	①④

T: Treatment group; C: Control group; ① T Cell subset ② Lung function; ③ Arterial blood gases; ④ Hospital stay; NR: Not reported.

Figure 1: Flow diagram of the literature search process.

A total of thirty-nine randomised controlled trials were included in this meta-analysis (Table I). All the studies used thymosin alpha 1 with routine complex treatment as the experimental group and routine complex treatment as the control group. Routine complex treatment can consist of antibiotics, anti-inflammatory, bronchial expansion, and resolving the phlegm. The duration of therapy was 1 to 12 weeks by intravenous or subcutaneous injection.

According to the criteria in the Cochrane Evaluation Handbook of RCTs, the methodological quality evaluation forms were formulated. The randomisation method used was described in 25 (64.1%) articles. The remaining trials only mentioned randomisation but failed to describe the method of randomisation. Two trials described the process of allocation concealment in sufficient detail.[9,34] Only one trial claimed to have used the blinded method.[9] The risk of outcome assessment was unclear. All the included trials had an unclear risk of bias of incomplete outcome data because insufficient information was provided. Other bias was evaluated as an unclear risk. The risk of bias assessment of all included studies was shown in Figure 2.

Twenty-five studies including CD4[+] T lymphocytes count[9,13-21,24,26,33-35,37,39-42,44-47] and the ratio of CD4[+]/CD8[+9,13-21,24-26,33-35,37,39-41,44-47] were evaluated after treatment. As the test of heterogeneity was 74% and 93%, respectively, a random effects model was used for the test. The meta-analysis revealed that the CD4[+] T lymphocytes count [MD = 7.54, 95% (6.66, 8.41), p <0.001] and the ratio of CD4[+]/CD8[+][MD = 0.40, 95% (0.34, 0.46), p <0.001] significantly raised after treatment. The CD8[+] T lymphocyte count was reported in 22 trials of 1927 patients.[9,13,14,16-18,20,21,24,33-35,37,39-42,44-47] There was statistical heterogeneity between the 2 groups (I^2 = 92%). The meta-analysis results revealed that the CD8[+] T lymphocytes count significantly decreased after the treatment [MD = -2.74, 95% (-3.86, -1.63), p <0.001] (Figure 3). Considering the lack of literature and relevant data, the authors did not conduct subgroup analyses.

Figure 2: Risk of methodological bias of the included studies.

A

| Study or Subgroup	Experimental Mean	SD	Total	Control Mean	SD	Total	Weight	Mean Difference IV, Random, 95% CI
Cui et al 2012	44.33	3.3	15	36.87	4.67	15	3.6%	7.46 [4.57, 10.35]
Fan 2017	42.75	4.75	45	32.48	5.01	45	4.5%	10.27 [8.25, 12.29]
Hu 2018	45.31	6.15	30	29.79	8.78	30	2.8%	15.52 [11.68, 19.36]
Jia et al 2015	35.96	7.98	42	31.62	7.22	42	3.2%	4.34 [1.09, 7.59]
Jiang 2018	43.57	7.52	133	35.78	8.57	124	4.5%	7.79 [5.81, 9.77]
Jiao 2017	44.58	4.06	41	36.38	4.65	41	4.6%	8.20 [6.31, 10.09]
Jin 2018	45.69	8.9	43	33.15	0.05	43	3.8%	12.54 [9.88, 15.20]
Jin et al 2012	39.7	7.4	37	32.4	5.1	40	3.6%	7.30 [4.44, 10.16]
Ju 2016	45.67	8.93	46	33.17	0.07	42	3.9%	12.50 [9.92, 15.08]
Li et al 2007	42.8	10.3	56	36.5	6.3	52	3.3%	6.30 [3.10, 9.50]
Lin et al 2016	45	4.56	40	37.56	3.75	40	4.7%	7.44 [5.61, 9.27]
Liu 2014	41.6	5.4	40	33.1	4.6	40	4.3%	8.50 [6.30, 10.70]
Liu et al 2014	43.86	5.6	60	36.69	5.03	60	4.6%	7.17 [5.27, 9.07]
Quan 2019	41.25	4.06	44	33.25	3.12	43	5.0%	8.00 [6.48, 9.52]
Shao 2013	44.4	3.5	40	36.9	4.7	40	4.7%	7.50 [5.68, 9.32]
Tong et al 2013	43.56	7.51	43	35.79	8.64	40	3.0%	7.77 [4.28, 11.26]
Wang et al 2017	48.6	4.7	50	42.2	4.6	50	4.7%	6.40 [4.58, 8.22]
Wu et al 2017	34.53	7.47	38	30.65	7.19	37	3.2%	3.88 [0.56, 7.20]
Xie 2016	45.76	3.88	30	41.28	3.95	30	4.5%	4.48 [2.50, 6.46]
Yang et al 2018	42.44	9.1	40	38.61	8.26	40	2.8%	3.83 [0.02, 7.64]
Ye 2019	45.1	3.4	53	39.8	3.1	52	5.2%	5.30 [4.06, 6.54]
Yu 2017	38.57	7.41	44	31.02	6.23	44	3.6%	7.55 [4.69, 10.41]
Yu 2018	42.3	9.1	35	38.1	8.8	35	2.5%	4.20 [0.01, 8.39]
Zhao et al 2016	48.6	4.7	50	42.2	4.6	50	4.7%	6.40 [4.58, 8.22]
Zhou 2018	45.08	2.86	39	37.5	3.65	39	5.0%	7.58 [6.12, 9.04]
Total (95% CI)			**1134**			**1114**	**100.0%**	**7.54 [6.66, 8.41]**

Heterogeneity: Tau² = 3.43; Chi² = 92.29, df = 24 (P < 0.00001); I² = 74%
Test for overall effect: Z = 16.83 (P < 0.00001)

Control / Thymosin alpha 1

B

Study or Subgroup	Experimental Mean	SD	Total	Control Mean	SD	Total	Weight	Mean Difference IV, Random, 95% CI
Cai 2019	1.36	0.19	33	1.23	0.25	32	5.5%	0.13 [0.02, 0.24]
Cui et al 2012	1.7	0.05	15	1.18	0.08	15	6.5%	0.52 [0.47, 0.57]
Fan 2017	1.93	0.42	45	1.93	0.43	45	4.3%	0.00 [−0.18, 0.18]
Hu 2018	2.17	0.48	30	1.25	0.39	30	3.5%	0.92 [0.70, 1.14]
Jia et al 2015	1.65	0.68	42	1.12	0.42	42	3.2%	0.53 [0.29, 0.77]
Jiang 2018	1.68	2.93	133	1.28	3.77	124	0.5%	0.40 [−0.43, 1.23]
Jiao 2017	1.71	0.08	41	1.2	0.06	41	6.6%	0.51 [0.48, 0.54]
Jin 2018	1.86	0.02	43	1.3	0.03	43	6.7%	0.56 [0.55, 0.57]
Jin et al 2012	1.5	0.6	37	1.2	0.4	40	3.4%	0.30 [0.07, 0.53]
Li et al 2007	1.75	0.38	56	1.23	0.4	52	4.8%	0.52 [0.37, 0.67]
Lin et al 2016	1.77	0.27	40	1.22	0.43	40	4.6%	0.55 [0.39, 0.71]
Liu 2014	1.34	0.47	40	1.87	0.63	40	3.2%	−0.53 [−0.77, −0.29]
Liu et al 2014	1.82	0.36	60	1.19	0.27	60	5.4%	0.63 [0.52, 0.74]
Quan 2019	1.35	0.38	44	1.89	0.63	43	3.6%	−0.54 [−0.76, −0.32]
Shao 2013	1.69	0.06	40	1.17	0.07	40	6.6%	0.52 [0.49, 0.55]
Tong et al 2013	1.69	2.94	43	1.3	3.78	40	0.2%	0.39 [−1.07, 1.85]
Wang et al 2017	2.3	0.4	50	1.7	0.5	50	4.2%	0.60 [0.42, 0.78]
Wu et al 2017	1.45	0.29	38	1.16	0.28	37	5.1%	0.29 [0.16, 0.42]
Xie 2016	2.16	0.8	30	1.78	0.76	30	1.7%	0.38 [−0.01, 0.77]
Yang et al 2018	2.15	0.78	40	1.54	0.61	40	2.5%	0.61 [0.30, 0.92]
Ye 2019	2.1	0.6	53	1.6	0.4	52	4.0%	0.50 [0.31, 0.69]
Yu 2017	1.79	0.46	44	1.42	0.43	44	4.1%	0.37 [0.18, 0.56]
Yu 2018	2.1	0.7	35	1.93	0.6	35	2.5%	0.17 [−0.14, 0.48]
Zhao et al 2016	1.89	0.65	30	1.35	0.49	30	2.6%	0.54 [0.25, 0.83]
Zhou 2018	1.78	0.25	39	1.23	0.42	39	4.7%	0.55 [0.40, 0.70]
Total (95% CI)			**1101**			**1084**	**100.0%**	**0.40 [0.34, 0.46]**

Heterogeneity: Tau² = 0.01; Chi² = 321.20, df = 24 (P < 0.00001); I² = 93%
Test for overall effect: Z = 12.95 (P < 0.00001)

Control / Thymosin alpha 1

C

Study or Subgroup	Experimental Mean	SD	Total	Control Mean	SD	Total	Weight	Mean Difference IV, Random, 95% CI
Cui et al 2012	26.07	2.11	15	31.27	2.44	15	4.8%	−5.20 [−6.83, −3.57]
Hu 2018	21.46	3.44	30	24.78	5.69	30	4.3%	−3.32 [−5.70, −0.94]
Jia et al 2015	24.58	5.83	42	29.89	6.08	42	4.2%	−5.31 [−7.86, −2.76]
Jiang 2018	24.7	9.73	133	28.71	6.48	124	4.6%	−4.01 [−6.02, −2.00]
Jiao 2017	26.58	2.19	41	31.28	2.28	41	5.1%	−4.70 [−5.67, −3.73]
Jin et al 2012	26.8	4	37	28.2	4.6	40	4.6%	−1.40 [−3.32, 0.52]
Ju 2016	29	4	46	28	4	42	4.8%	1.00 [−0.67, 2.67]
Li et al 2007	24.4	9.8	56	29.8	9.7	52	3.4%	−5.40 [−9.08, −1.72]
Lin et al 2016	25.48	1.64	40	30.7	2.16	40	5.2%	−5.22 [−6.06, −4.38]
Liu 2014	29.2	3.7	40	28.1	3.6	40	4.8%	1.10 [−0.50, 2.70]
Liu et al 2014	24.33	7.38	60	30.42	6.17	60	4.3%	−6.09 [−8.52, −3.66]
Quan 2019	29.31	2.75	44	28.06	2.62	43	5.1%	1.25 [0.12, 2.38]
Shao 2013	26.1	2.5	40	31.3	2.3	40	5.1%	−5.20 [−6.25, −4.15]
Tong et al 2013	24.69	9.74	43	28.73	6.52	40	3.5%	−4.04 [−7.58, −0.50]
Wang et al 2017	21.2	1.7	50	23.3	2.2	50	5.2%	−2.10 [−2.87, −1.33]
Wu et al 2017	23.86	5.4	38	26.47	5.16	37	4.3%	−2.61 [−5.00, −0.22]
Xie 2016	21.82	2.26	30	23.97	2.85	30	5.0%	−2.15 [−3.45, −0.85]
Yang et al 2018	21.3	6.52	40	24.56	8.17	40	3.7%	−3.26 [−6.50, −0.02]
Yu 2017	22.45	3.55	44	26.36	3.4	44	4.9%	−3.91 [−5.36, −2.46]
Yu 2018	21.5	6.5	35	24.8	8.5	35	3.5%	−3.30 [−6.85, 0.25]
Zhao et al 2016	29.1	3.9	30	28.2	3.8	30	4.6%	0.90 [−1.05, 2.85]
Zhou 2018	31.27	1.58	39	30.75	2.16	39	5.2%	0.52 [−0.32, 1.36]
Total (95% CI)			**973**			**954**	**100.0%**	**−2.74 [−3.86, −1.63]**

Heterogeneity: Tau² = 6.08; Chi² = 261.23, df = 21 (P < 0.00001); I² = 92%
Test for overall effect: Z = 4.82 (P < 0.00001)

Thymosin alpha 1 / Control

Figure 3: Forest plot. (A) CD4+ (B) CD4+/CD8+ C) CD8+.

Figure 4: Forest plot. (A) FEV1 (B) FEV1/FVC.

Twenty-three studies including 1,881 patients of AECOPD patients were evaluated for the forced expiratory volume in the first second (FEV1).[9-12,15,18,19,23,24,26-31,35-39,41-43] The ratio of forced expiratory volume in the first second to forced vital capacity (FEV1/FVC) was evaluated and analysed in 15 studies.[9,11,14,15,18, 24,27-29,35-37,39,40] The test of heterogeneity was 63% and 97% (p <0.01), respectively, suggesting that a random-effects model was preferred. Due to the significant heterogeneity, a subgroup analysis was conducted according to the duration of treatment to explore the sources of hetero-geneity. This meta-analysis indicated that there were statistically significant differences between the two groups for FEV1 [MD = 0.29, 95% (0.26, 0.32), p <0.001] and FEV1/FVC [MD = 6.24, 95% (3.83, 8.65), p <0.001], which revealed that thymosin α1 was beneficial to the improvement of pulmonary function (Figure 4).

Seven studies involving 564 participants were included in the meta-analysis to explore the impact of thymosin alpha 1 on arterial blood gases by random-effects model.[9,14,18,35,36,39,41]

Figure 5: Forest plot. (A) the partial pressure of the arterial partial pressure of oxygen (B) the arterial partial pressure of carbon dioxide (C) length of hospital stay.

Figure 6: Sensitivity analysis. (A) CD4+ (B) CD8+.

The results of the pooled analysis indicated that thymosin alpha 1 significantly increased the arterial partial pressure of oxygen [MD = 7.24, 95% (3.42, 11.07), p = 0.0002, I^2 = 89%] and lowered the arterial partial pressure of carbon dioxide [MD = -5.85, 95% (-9.38, -2.33), p = 0.001, I^2 = 94%] (Figure 5). A total of three studies involving 237 patients

presented length of hospital stay.[35,46,47] The test of heterogeneity was 68% (p = 0.05), suggesting that a random-effects model was preferred. As shown in Figure 5, the pooled results suggested a significant difference for the length of hospital stay [MD = -5.39, 95% (-7.82, -2.97), p <0.001].

A single study involved in the meta-analysis was deleted each time, and the rest was reanalysed, resulting in similar results compared with the previous ones, indicating that the present study's results were statistically robust. For further verification, the authors implemented a sensitivity analysis of the CD4[+] and CD8[+] T lymphocyte count by Stata 14.0. Figure 6 indicated that the outcomes were very similar, and had relatively good stability. The funnel plot was applied to assess the publication bias of studies that included the results of the CD4+ T lymphocyte count in this meta-analysis, which showed a significant asymmetry. Egger's test was further performed to assess publication bias. The results for CD4+ T lymphocyte count (p = 0.064) revealed that publication bias might exist in the present study.

DISCUSSION

Recently, accumulated evidence has suggested that autoimmune response plays an important role in the pathogenesis of COPD, and T lymphocytes are believed to be the key cells in regulating airway inflammation in COPD.[48] T lymphocytes subpopulation can be subdivided into T helper lymphocytes and T inhibiter lymphocytes. CD4[+] T lymphocytes are a marker for T helper lymphocytes. CD4[+] T lymphocytes can activate T lymphocytes and participate in inducing cellular immune responses. CD8[+] T lymphocytes are a marker of T inhibiter lymphocytes. CD8[+] T lymphocytes have cytotoxic effects and exert inhibitory effects on T lymphocytes' activity.[49] Many animal experiments have verified that thymosin alpha 1 stimulated precursor stem cells into the CD4[+]/CD8[+] T cells, promoted T-cell maturation, meanwhile modulated lymphocyte phenotypic marker expression and immune response.[50] This meta-analysis revealed that the CD4[+] T lymphocytes count and the ratio of CD4[+]/CD8[+] significantly raised after treatment, while the CD8[+] T lymphocyte count significantly decreased after treatment. These results suggested that thymosin alpha 1 could enhance the activity of helper T cells, consequently improving cellular immune function and anti-infection ability.

The results of the meta-analysis showed that the arterial partial pressure of oxygen and carbon dioxide, and the indices of pulmonary function (FEV1 and FEV1/FVC) in the experimental group were significantly improved after treatment. AECOPD is characterised by a sudden worsening of COPD symptoms, which typically leads to decreased lung function, an increased incidence of respiratory failure, and even death. Some studies have shown that increased numbers of CD8[+] T cells and reduced ratio of CD4[+]/CD8[+] T cells in COPD patients have been correlated with a decline in lung function.[51] An inability to upregulate Tregs could lead to a more rapid development of emphysema, and thus to a more rapid decline in lung function.[52] On the other hand, thymosin alpha 1 specifically potentiates immune tolerance in the lung, often breaking the vicious circle that perpetuates chronic lung inflammation in response to a variety of infectious noxae.[53] Hence, thymosin alpha 1 might be adopted in improving pulmonary function and arterial blood gas with AECOPD patients.

This study has certain limitations. First, the bias risk of many studies was unknown. Risk of bias assessments for the randomisation and concealment allocation were frequently inadequate. Second, the thymosin alpha 1 intervention protocol, including frequency and sessions, varied greatly across studies. This could influence the reliability of the pooled effect sizes and make it difficult for the review authors to draw a definitive conclusion about the optimal recommendation. Third, the meta-analysis showed considerable evidence of heterogeneity between trials. The average illness severity, and age differed from trial-to-trial and the diversity of treatment options might be the source of heterogeneity. Considering the lack of literature and relevant data, the authors did not conduct subgroup analyses. Therefore, more well-designed trials in the near future are a feasible solution to remedy this flaw.

CONCLUSION

This is the first systematic review and meta-analysis to evaluate the effectiveness of thymosin alpha 1 in the acute exacerbation of chronic obstructive pulmonary disease (AECOPD) patients. Thirty-nine randomised controlled trials including 3,329 patients were included in the analysis, which ensured adequacy specimen to precisely evaluate the efficacy. By the results of this meta-analysis, the authors concluded that thymosin alpha 1 plus routine treatment could more efficiently enhance the immune function, and improve pulmonary function, and arterial blood gas of AECOPD patients than routine treatment only. However, some big international multi-centred and high-quality RCTs are urgently needed to further prove the efficacy.

COMPETING INTEREST:
The authors declared no conflict of interest.

AUTHORS' CONTRIBUTION:
XZ, AC: Conceived and designed the project.
AC, FF: Performed the review and analysed the data.
AC: Wrote the paper.
XZ: Was responsible for quality control of the study.
All authors approved the final version of the manuscript to be published.

REFERENCES

1. Wang C, Xu J, Yang L, Xu Y, Zhang X, Bai C, *et al*. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): A national cross-sectional study. *Lancet* 2018; **391(10131)**:1706-17. doi: 10.1016/S0140-6736(18)30 841-9.

2. Riley CM, Sciurba FC. Diagnosis and outpatient management of chronic obstructive pulmonary disease: A review. *JAMA* 2019; **321(8)**:786-97. doi:10.1001/jama.2019. 0131.

3. Dobler CC, Morrow AS, Farah MH, Beuschel B, Majzoub AM, Wilson ME, *et al*. Nonpharmacologic therapies in patients with exacerbation of chronic obstructive pulmonary disease: A systematic review with meta-analysis. *Mayo Clin Proc* 2020; **95(6)**:1169-83. doi: 10.1016/j.mayocp.2020.01.018.

4. Hou J, Sun Y. Role of regulatory t cells in disturbed immune homeostasis in patients with chronic obstructive pulmonary disease. *Front Immunol* 2020; **11**:723. doi: 10.3389/fimmu.2020.00723.

5. Dominari A, Hathaway IiiD, Pandav K, Matos W, Biswas S, Reddy G, *et al*. Thymosin alpha 1: A comprehensive review of the literature. *World J Virol* 2020; **9(5)**:67-78. doi: 10.5501/wjv.v9.i5.67.

6. Wu XL, Wang H, Ge L. The curative effect of thymosin-α1 in the adjuvant treatment of senile patients with AECOPD: A Meta-analysis. *Chinese J Clinicians* 2015; **9(1)**:93-9. doi: 10.3877/cma.j.issn.1674-0785.2015.01. 013.

7. Chen YH, Feng CL, Wang J, Wang W, Xie JG, Yin Y. Expert consensus on immunomodulatory therapies for chronic obstructive pulmonary disease. *Chinese General Practice* 2022; **25(24)**:2947-59. doi: 10.12114/j.issn.1007-9572. 2022.0384.

8. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration. Available form: http://www.cochrane.org/ training/cochrane hand book.2011.

9. [9] Jia Z, Feng Z, Tian R, Wang Q, Wang LYl. Thymosin α1 plus routine treatment inhibit inflammatory reaction and improve the quality of life in AECOPD patients. *Immunopharmacol Immunotoxicol* 2015; **37(4)**:388. doi: 10.3109/08923973.2015.1069837.

10. Wu XP. Efficacy evaluation of antibiotics combined with thymosin in the treatment of acute exacerbation of chronic obstructive pulmonary disease in elderly patients. *Modern Med Health Res* 2019; **3(18)**:59-61. doi: CNKI:SUN:XYJD.0.2019-18-027.

11. Sun W, Li BX, Zhang M. Clinical study of antibiotic combined with thymosin in the treatment of acute exacerbation of chronic obstructive pulmonary disease in the elderly. *Healthful Friend* 2019; **9(17)**:24.

12. Fan YJ. Clinical study of antibiotic combined with thymosin in the treatment of acute exacerbation of chronic obstructive pulmonary disease in the elderly. *J North Pharmacy* 2017; **14(1)**:34-5. doi: 10.3969/j.issn. 1672-8351.2017.01.025.

13. Xie X. Effect of thymosin α1 on cellular and humoral immune function in patients with acute exacerbation of chronic obstructive pulmonary disease. *J Clin Pulmonary Med* 2016; **21(6)**:1031-4. doi: 10.3969/j.issn.1009-6663. 2016.06.019.

14. Tong WN, Zhuo AS, Cao YS, Xu SL. Clinical observation of thymosin α1 adjuvant therapy in acute exacerbation of elderly patients with chronic obstructive pulmonary disease. *Chinese Pharmacist* 2013; **16(4)**:600-3. doi: 10.14163/j.cnki.11-5547/r.2018.24.005.

15. Fan HJ. The clinical efficacy of thymosin α1 adjuvant therapy in elderly patients with acute exacerbation of chronic obstructive pulmonary disease. *Current Med* 2017; **23(32)**:117-9. doi: 10.3969/j.issn.1009-4393. 2017.32.051.

16. [16] Yang XY, Liu Y. Effects of thymosin on T lymphocyte subsets in patients with acute exacerbation of chronic obstructive pulmonary disease. *Chinese J Convalescent Medicine* 2018; **27(10)**:92-3. doi: 10.13517/j.cnki.ccm. 2018.10.037.

17. Zhou X. Effect of thymosin on T lymphocyte subsets in acute exacerbation of COPD. *Clin Res Prac* 2019; **3(34)**:57-8. doi: 10.19347/j.cnki.2096-1413.201834022.

18. Yu CH. Effect of thymosin on T lymphocyte subsets in acute exacerbation of chronic obstructive pulmonary disease. *J Clin Pulmonary Med* 2016; **21(4)**:670-3. doi: 10.3969/j.issn.1009-6663.2016.04.026.

19. Ye ZY. Effect of thymosin on T lymphocyte subsets in patients with acute exacerbation of chronic obstructive pulmonary disease. *J Clinical Medicine* 2019; **6(65)**:67-8.

20. Hu DN. The effect of thymosin on cellular immunity in patients with stable COPD. Hangzhou Normal University. 2018.

21. Wang CX, Wang XH, Wang Y, Bi XM, Dong HQ. The effect of thymosin on immune function in patients with severe chronic obstructive pulmonary disease. *World Latest Medical Information Abstracts* 2017; **17(31)**:165.

22. Shao LQ. Effect analysis of thymosin combined with antibiotics on acute exacerbation of chronic obstructive pulmonary disease in elderly. *Health Readings* 2019; **12(34)**:137-8.

23. Zhang LY. Thymosin combined with antibiotics in the treatment of acute exacerbation of chronic obstructive pulmonary disease in the elderly. *Modern Diagnosis Therapy* 2016; **27(3)**:502-3. doi: CNKI:SUN:XDZD.0. 2016-03-074.

24. Zhao ZY, Xie YT, Gao X. Clinical efficacy of thymosin combined with antibiotics in the treatment of acute exacerbation of chronic obstructive pulmonary disease in elderly patients. *Chinese J Primary Medicine* 2016; **23(16)**:2537-41. doi: 10.3760/cma.j.issn.1008-6706. 2016.16.036.

25. Cai ZQ. Therapeutic effect of thymosin combined with antibiotics in patients with acute exacerbation of chronic obstructive pulmonary disease and pulmonary infection, *Capital Food and Medicine* 2019; **9(17)**:63. doi:10.3969/j.issn.1005-8257.2019.17.053.

26. Jin X. Application analysis of thymosin combined with antibiotics in the treatment of acute exacerbation of chronic obstructive pulmonary disease in the elderly. *Chinese Medicine Guide* 2018; **16(3)**:73-4. doi: CNKI:-SUN:YYXK.0.2018-03-060.

27. Guo X. The application of thymosin combined with antibiotics in the treatment of acute exacerbation of chronic obstructive pulmonary disease in elderly. *Chinese J Health Nutrition* 2016; **26(30)**:244-5. doi: 10.3969/j.issn.1004-7484.2016.30.390.

28. Quan AF. Effectiveness of thymosin combined with antibiotics in the treatment of elderly patients with acute exacerbation of chronic obstructive pulmonary disease. *Drug Evaluation* 2019; **16(24)**:63-4. doi: 10.3969/j.issn.1672-2809.2019.24.035.

29. Wang LH. Therapeutic effect analysis of thymosin combined with cefazolin sodium pentahydrate in elderly patients with acute exacerbation of chronic obstructive pulmonary disease. *China Practical Medicine* 2019; **14(19)**:2. doi: 10.14163/j.cnki.11-5547/r.2019.19.055.

30. Zhang SJ. Effect of combined administration of thymosin and cephazolin pentahydrin sodium on pulmonary function in elderly patients with acute exacerbation of chronic obstructive pulmonary disease. *Doctors* 2020; **10**:375-6.

31. Zhao XD, Wang LL. Clinical efficacy of thymosin combined with cefezolin pentahydrin sodium in elderly patients with acute exacerbation of chronic obstructive pulmonary disease. *Anti-infective Pharmacy* 2018; **15(10)**:1684-6. doi: 10.13493/j.issn.1672-7878.2018.10-008.

32. Peng AH. Therapeutic effect of thymosin combined with meloxicillin on elderly patients with acute exacerbation of chronic obstructive pulmonary disease. *J Contemporary Med* 2015; **13(22)**:159-60. doi: CNKI:SUN:QYWA.0.2015-22-137.

33. Cui DP, Zhou W, Qi ZY. Effect of thymosin α1 on cellular immune function in elderly patients with acute exacerbation of chronic obstructive pulmonary disease. *Strait Pharmacy* 2012; **24(4)**:153-4. doi:10.3969/j.issn.1006-3765.2012.04.081.

34. Jiao JH. Effect of thymosin α1 on cellular immune function in elderly patients with acute exacerbation of chronic obstructive pulmonary disease. *Med Theory Prac* 2017; **30(22)**:3347-8. doi: 10.19381/j.issn.1001-7585.2017.22.027.

35. Liu H. Efficacy of thymosin α1 in the treatment of acute exacerbation of chronic obstructive pulmonary disease in elderly patients. *Shandong Med* 2014; **54(33)**:50-1. doi: CNKI:SUN:SDYY.0.2014-33-023.

36. Li J. Clinical efficacy on inflammatory factors and lung function of thymosin α1 in acute exacerbation of chronic obstructive pulmonary disease patients. *Chinese Modern Doctor* 2018; **56(34)**:28-31. doi: CNKI:SUN:ZDYS.0.2018-34-008.

37. Lin YZ, Yan H, Chen HW. Effects of thymosin on cellular immune function in patients with acute exacerbation of chronic obstructive pulmonary disease. *J Clin Pulmonary Med* 2016; **21(7)**:1216-9. doi: 10.3969/j.issn.1009-6663.2016.07.015.

38. Le YH. Efficacy and safety of thymosin combined with antibiotics in the treatment of acute exacerbation of chronic obstructive pulmonary disease in elderly patients. *Chinese J Gerontology* 2013; **33(19)**:4703-5. doi: 10.3969/j.issn.1005-9202.2013.19.018.

39. Wu XZ, Yuan F. The role of thymosin in the clinical treatment of acute exacerbation of chronic obstructive pulmonary disease. *J North Sichuan Med Coll* 2017; **32(6)**:923-5. doi: 10.3969/j.issn.1005-3697.2017.06.034.

40. [Jiang R. Clinical efficacy of thymosin on immune function in acute exacerbation of chronic obstructive pulmonary disease. *Modern Diagnosis Treatment* 2018; **29(3)**:449-50. doi: CNKI:SUN:XDZD.0.2018-03-057.

41. Yu HX, Cai DD. Clinical study on the treatment of acute exacerbation of chronic obstructive pulmonary disease with thymosin and antimicrobial agents. *Laboratory Med Clinic* 2017; **14(14)**:2146-8. doi: 10.3969/j.issn.1672-9455.2017.14.055.

42. Ju J. Clinical effect of thymosin combined with antibiotics on elderly patients with acute exacerbation of chronic obstructive pulmonary disease. *J Pharmaceutical Economics* 2016; **11(8)**:67-8. doi: CNKI:SUN:ZYWA.0.2016-08-025.

43. Su CZ. Clinical effect on pulmonary function of thymosin combined with antibiotics in the treatment of chronic obstructive pulmonary disease. *Women's Health Research* 2018; **4(7)**:44-8. doi: 10.3969/j.issn.2096-0417.2018.07.023.

44. Li CH, Wang CH, Meng QH, Ye XL, Wang XJ, Jiang C. Effect of thymosin α1 on immune function in elderly patients with chronic obstructive pulmonary disease. *Chinese J Hospital Pharmacy* 2007; **27(5)**:637-9. doi: 10.3321/j.issn:1001-5213.2007.05.026.

45. Liu MC, Liu L, Song D. The effect of thymosin α1 on acute onset of chronic obstructive pulmonary disease in elderly patients. *Southwest National Med J* 2014; **24(6)**:598-601. doi: CNKI:SUN:XNGF.0.2014-06-009.

46. Shao W. Thymosin α1 in the treatment of 40 elderly patients with acute exacerbation of chronic obstructive pulmonary disease. *Chinese J Gerontology* 2013; **14**:3488-9. doi: 10.3969/j.issn.1005-9202.2013.14.118.

47. Jin YK, Ye XW, Xu YJ. Effects of thymosin α1 on cellular immune function in elderly patients with acute exacerbation of chronic obstructive pulmonary disease. *Chinese J Experimental Diagnostics* 2012; **16(12)**:2268-9. doi: 10.3969/j.issn.1007-4287.2012.12.039.

48. Sun J, Liu T, Yan Y, Huo K, Zhang W, Liu H, *et al*. The role of Th1/Th2 Cytokines played in regulation of specific

CD4+ Th1 cells conversion and activation during inflammatory reaction of chronic obstructive pulmonary disease. *Scand J Immunol* 2018; **88(1)**:e12674. doi: 10.1111/sji.12674.

49. [Yan ZY, Liu NX, Mao XX, Li Y, Li CT. Activation effects of polysaccharides of flammulina velutipes mycorrhizae on the T lymphocyte immune function. *J Immunol Res* 2014; **4**:e285421. doi: 10.1155/2014/285421.

50. Shao C, Tian G, Huang Y, Liang W, Zheng H, Wei J, *et al*. Thymosin alpha-1-transformed bifidobacterium promotes T cell proliferation and maturation in mice by oral administration. *Int Immunopharmacol* 2013; **15(3)**:646-53. doi: 10.1016/j.intimp.2012.12.031.

51. Wang CY, Ding HZ, Tang X, Li ZG. Effect of Liuweibuqi capsules on CD4$^+$CD25$^+$Foxp3$^+$ regulatory T cells, helper T cells and lung function in patients with stable chronic obstructive pulmonary disease complicated with lung Qi deficiency. *J Thorac Dis* 2018; **10(5)**:2700-11. doi: 10. 21037/jtd.2018.04.110.

52. Strm JE, Pourazar J, Linder R, Blomberg A, Lindberg A, Bucht A, *et al*. Airway regulatory T cells are decreased in COPD with a rapid decline in lung function. *Resp Res* 2020; **21(1)**:330. doi: 10.1186/s12931-020-01593-9.

53. Camerini R, Garaci E. Historical review of thymosin α 1 in infectious diseases. *Expert Opin Biol Ther* 2015; **15 (Suppl 1)**:S117-27. doi: 10.1517/14712598.2015.1033393.

• • • • • • • • •